Pyrrolo[1,2-b][1,2,5] benzothiadiazepines (PBTDs):: A new class of agents with high apoptotic activity in chronic myelogenous leukemia K562 cells and in cells from patients at onset and who were imatinib-resistant

被引:64
作者
Silvestri, Romano
Marfe, Gabriella
Artico, Marino
La Regina, Giuseppe
Lavecchia, Antonio
Novellino, Ettore
Morgante, Manuela
Di Stefano, Carla
Catalano, Gianfranco
Filomeni, Giuseppe
Abruzzese, Elisabetta
Ciriolo, Maria Rosa
Russo, Matteo Antonio
Amadori, Sergio
Cirilli, Roberto
La Torre, Francesco
Salimei, Paola Sinibaldi
机构
[1] Univ Roma La Sapienza, Dipartimento Studi Farmaceut, Ist Pasteur, Fdn Cenci Bolognetti, I-00185 Rome, Italy
[2] Univ Roma Tor Vergata, Dipartimento Med Sperimentale & Sci Biochim, I-00133 Rome, Italy
[3] Univ Naples Federico II, Dipartimento Chim Farmaceut & Tossicol, I-80131 Naples, Italy
[4] Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, I-00161 Rome, Italy
[5] Univ Roma Tor Vergata, Osped Sant Eugenio, Cattedra Ematol, I-00144 Rome, Italy
[6] Univ Roma Tor Vergata, Dipartimento Biol, I-00133 Rome, Italy
[7] Ist Super Sanita, Dipartimento Farm, I-00161 Rome, Italy
关键词
CHRONIC MYELOID-LEUKEMIA; BCR-ABL; HETEROCYCLES; DERIVATIVES; MECHANISMS; SURVIVAL; BIOLOGY; MOIETY;
D O I
10.1021/jm0602716
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Pyrrolo[1,2-b][1,2,5]benzothiadiazepine 5,5-dioxides (PBTDs) induced apoptosis in human BCR-ABL-expressing leukemia cells. The apoptotic activity was also observed in primary leukemic blasts, obtained from chronic myelogenous leukemia (CML) patients at onset or from patients in blast crisis and who were imatinib-resistant. Compounds 5 and 14 induced apoptosis before BCR-ABL protein expression and tyrosin phosphorylation were affected and activated different caspases in the apoptotic pathway. PBTDs are a new class of valid candidates for the treatment of CML.
引用
收藏
页码:5840 / 5844
页数:5
相关论文
共 23 条
[1]   5H-Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs): A novel class of non-nucleoside reverse transcriptase inhibitors [J].
Artico, M ;
Silvestri, R ;
Pagnozzi, E ;
Stefancich, G ;
Massa, S ;
Loi, AG ;
Putzolu, M ;
Corrias, S ;
Spiga, MG ;
LaColla, P .
BIOORGANIC & MEDICINAL CHEMISTRY, 1996, 4 (06) :837-850
[2]   BCR-ABL-MEDIATED INHIBITION OF APOPTOSIS WITH DELAY OF G2/M TRANSITION AFTER DNA-DAMAGE - A MECHANISM OF RESISTANCE TO MULTIPLE ANTICANCER AGENTS [J].
BEDI, A ;
BARBER, JP ;
BEDI, GC ;
ELDEIRY, WS ;
SIDRANSKY, D ;
VALA, MS ;
AKHTAR, AJ ;
HILTON, J ;
JONES, RJ .
BLOOD, 1995, 86 (03) :1148-1158
[3]   Bcr-Abl-mediated resistance to apoptosis is independent of constant tyrosine-kinase activity [J].
Bueno-da-Silva, AEB ;
Brumatti, G ;
Russo, FO ;
Green, DR ;
Amarante-Mendes, GP .
CELL DEATH AND DIFFERENTIATION, 2003, 10 (05) :592-598
[4]  
CHIMENTI F, 1974, FARMACO-ED SCI, V29, P589
[5]   JAK-STAT signaling activated by Abl oncogenes [J].
Danial, NN ;
Rothman, P .
ONCOGENE, 2000, 19 (21) :2523-2531
[6]   Imatinib Mesilate -: Treatment of chronic myeloid leukemia Brc-Abl tyrosine kinase inhibitor [J].
de Bree, F ;
Sorbera, LA ;
Fernández, R ;
Castañer, J .
DRUGS OF THE FUTURE, 2001, 26 (06) :545-552
[7]   The development of imatinib as a therapeutic agent for chronic myeloid leukemia [J].
Deininger, M ;
Buchdunger, E ;
Druker, BJ .
BLOOD, 2005, 105 (07) :2640-2653
[8]   Chronic myelogenous leukemia: Biology and therapy [J].
Faderl, S ;
Talpaz, M ;
Estrov, Z ;
Kantarjian, HM .
ANNALS OF INTERNAL MEDICINE, 1999, 131 (03) :207-219
[9]   Mechanisms of disease - The biology of chronic myeloid leukemia [J].
Faderl, S ;
Talpaz, M ;
Estrov, Z ;
O'Brien, S ;
Kurzrock, R ;
Kantarjian, HM .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (03) :164-172
[10]   CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs [J].
Fang, GF ;
Kim, CN ;
Perkins, CL ;
Ramadevi, N ;
Winton, E ;
Wittmann, S ;
Bhalla, KN .
BLOOD, 2000, 96 (06) :2246-2253